前苏联专利SU1384203A3 Method of producing peptidyl-arginine-aldehyde sulfates

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
The invention relates to peptide derivatives, in particular the preparation of peptidyl-arginine dehydrogen (SP) sulphates. The goal is to create new active substances of peptide nature with selective inhibition of blood coagulation. Synthesis of joint venture general f-ly: ,, - -DPhe-Pro-A-H H, S04, where R, - H; Rj is C, 4 alkyl; R and R are attached to NH Tpynne D-phenylalanine; And - the rest of L-arginine, lead by condensation of arginine-lactam with protected guanidino group and protected on the terminal amino group of the dipeptide N-monoalkyl (C) -b-proline. The resulting tripeptide lactam is reduced to aldehyde and, after cleavage of the protective groups, the desired product is isolated in the form of a sulfate salt. Yield,%: gross f-la: a) 75; 0.39-0.47; (-131) &; C x7 / 8 () 2.5 (H20); b) 70; 0.4-0.5; not; 5/6 (H jSO) x 3.5 (H20); at). 80; 0.64; not; C2, H380, N, -H S04-4 (); e) 67; 0.85-0.7; not. New SPs show anti-thrombin activity (in comparison with the control, clotting time increases by five times), affect the plasminfibrin response, are stable over time, and their minimum active dose is 1-2 mg / kg. 3 tab. § SAE 00 and 1HE
公开号:SU1384203A3
申请号:SU3992296
申请日:1985-12-20
公开日:1988-03-23
发明作者:Байус Шандор；Селл Эржебет；Багди Даниель；Барабаш Ева；Диосеги Марианн；Фиттлер Жужа；Йожа Ференц；Хорват Дьюла；Томори Ева
申请人:Рихтер Гедеон Ведьесети Дьяр Рт (Инопредприятие)；
IPC主号:

专利说明:

The invention relates to a method for producing peptidyl-aldehyde sulphates, new biologically active compounds that can be used in medicine.
The purpose of the invention is the creation of new compounds of peptide nature with selective inhibition of blood coagulation, but more than one hundred.
mobile and not prone to irreversible cyclization.
Rp values are determined by chromatography on a thin layer on silica gel (Kieselgel G Reanal, Budapest) using a mixture of solvents as eluent. Acetic acid ethyl ester pyridine, acetic acid and water at ratios (960: 20: 6: 11);
(480: 20: 6: 11); (240: 20: 6: 11); (120:: 20: 6: 11); (60:20: 6: 11); (30: 20: 6:: 11).
Example 1. Sulfate of N-methyl-D-phenyl-nin-L-np olyl-L-apr inin-aldehyde.
Step 1. K-Benzyloxycarbonyl-N-methyl-B-phenylalanine-L-prolyl-K - -benzyloxycarbonyl-L-arginine-lactam.
42.95 g (0.11 mol) of N-tert-butyloxycarbonyl-N-benzyloxycarbonyl-b-arginine-lactam is suspended in 110 ml of anhydrous chloroform, after which the suspension is mixed with 275 ml of a solution of hydrogen chloride in ethyl Acetic acid ester (concentration 0.11-0.15 g / ml). After stirring for 3 hours, the reaction mixture is diluted by adding 400 ml of diethyl ether, the crystalline mass precipitated. It is filtered off, the precipitate is washed twice with 100 ml of the latter, and then washed twice with acetone, apply each time 50 ml of the latter. Then the product is dried in a vacuum desiccator over phosphorus pentoxide and potassium hydroxide. After drying for approximately 1 hour, the compound is dissolved in 100 ml of dimethylformamide, the prepared solution is cooled to -15 ° C, after which, at the indicated temperature and with stirring, 20 ml of triethylamine are then added to the solution in this way so that in the gas phase
five
0
0
5 0 5 g
0
it was detectable overflow of the base. The suspension is added to the following mixed anhydride.
50.9 g (0.1 mol) of the cyclohexylammonium salt of N-benzyloxycarbonyl-K-methyl-B-phenylalanine-L-proline is dissolved in 200 ml of diethyl ether and 120 ml of 1N. sulfuric acid solution. The diethyl ether phase is washed three times with water, each time using 30 ml of the latter, dried over anhydrous sodium sulphate, and then evaporated on a water bath at a pressure of 25-30 mbar. The residue obtained and 11.2 ml (0.1 mol) of N-methylmorpholine are dissolved in 70 ml of dimethylformamide, the solution is cooled to –15 ° C, and then 13.2 ml (0.1 mol) is mixed at this temperature. isobutyloxycarbonyl chloride. Then (after 3-5 minutes) the mixture is additionally stirred for 5 minutes, after which this suspension is added to the resulting: mixed aldehyde in dimethylformamide. The reaction mixture is stirred for 1 hour at and for 1 hour at 0 ° C, then the mixture is diluted by adding 200 ml of benzene, after which the crystalline product precipitated is filtered off.
A solution of the product in benzene and dimethylformamide is diluted by adding 150 ml of water, after which the phases are separated. The lower one, which contains water, - the dimethylformamide phase is extracted three times with benzene, each time using 50 ml of the latter. The combined benzene solutions are washed three times with water, each time using 30 ml of the latter, dried over anhydrous sodium sulfate, and then evaporated in a water bath at a temperature of 40 ° C maximum and a pressure of 20-25 mbar.
The oily residue obtained is dissolved in 60 ml of a mixture consisting of benzene and tetrahydrofuran (8: 2), after which the solution is chromatographed on a column filled with 750 g of silica gel -60 using the same solvent mixture as an eluent. Fractions were analyzed by thin layer chromatography on silica gel using a mixture of solvents as eluent;
from pyridine ethyl acetate, acetic acid and water 480: 20: 6: 11. The target product has an Rp value of 0.70-0.76. The fractions in which the pure main product is contained are combined and evaporated in a water bath at a temperature of max 11mum 0 ° C and a pressure of 20-25 mbar to a volume of 100 ml. The resulting concentrate is mixed with 500 m of petroleum ether. The resulting suspension is filtered, the filter residue is washed twice with petroleum ether, each time using 100 ml of the latter, and then dried in a vacuum desiccator over sulfuric acid and paraffin chips.
. Output 45 g (65%). o +13.5 (s 1, tetrahydrofuran). , 70- O, 76.
Calculated,%: C 65.08; H 6.20; N 12.31.
C3, H ,, 0, N, (682.75)
Found,%: C 65.4; H 6.4; N 12.1.
Stage 2. N-Benzyloxycarbonyl- -Y-methyl-B-phenylalanine-L-prolyl-M - -benzyloxycarbonyl-L-arginineldehyde, 34, 15 g (0.05 mol) of N-benzyloxy carbonyl-K-methyl- B-phenylalanine-L- -rolyl-N-benzyloxycarbonyl-b-argin-lactam (example 1, step 1) is dissolved in 150 ml of tetrahydrofuran, after which the prepared solution is mixed with stirring with 0.0375 mol of lithium aluminum hydride in tetrahydrofuran . The reduction process is monitored by thin layer chromatography using c. as an eluent of the solvent mixture consisting of ethyl acetate, pyridine, acetic acid, and water 240: 20: 6: 11, (R p values for lacquer and aldehyde are respectively (-0, 5). In If necessary, additional lithium aluminum hydride is added. Then, with stirring and cooling, the pH of the reaction solution is adjusted to a value of 2 by adding 1N sulfuric acid solution. The solution is diluted with water until it becomes opalescent (approximately 300 ml), and then twice hexane injection, each time using 100 ml of the latter.
five
0
the tetrahydrofuran solution containing water is extracted twice with 250 NP of methylene chloride, the combined methylene chloride extracts are successively washed twice with water, each time using 50 ml of the latter two times with a 5% solution of sodium hydrogen carbonate, each time using 60 ml of this solution, and again twice with water, each time used 50 ml of the latter, dried over anhydrous sodium sulfate, and then evaporated in a water bath at a maximum temperature and pressure of 20-25 mbar to a volume of 50-60 ml. The residue is mixed with 100 ml of benzene, and then evaporated as described. The resulting residue is diluted by adding 100 ml of cyclohexane, the precipitate formed is filtered off, washed twice with cyclohexane, each time using 30 ml of the last 5, and then dried in a vacuum desiccator over paraffin chips.
The yield of 27 g (70%) of the product, which in accordance with the data of elemental analysis, contains 1 mol of cyclohexane. R 0,52-0,62. + 16, -8 ° (with 1, tetrahydrofuran).
Calculated,%: C 67.16; H 7.34; N 10.93.
С5, Н „О.К, -С, Н, g (768.93)
Found,%: C66.6; H7.2; N 10.4.
Stage 3. L-methyl-B-phenylalanine-L-prolyl-b-arginine dehydrate sulfate.
23.1 g (0.03 mol) of N-benzyloxy-carbrnyl-N-methyl-B-phenylalanine-L-prolyl-N-benzyloxycarbonyl-L-ap-: gininaldehyde (Example 1, Step 2) is dissolved in 150 ml of ethyl alcohol. The prepared solution is mixed with 50 ml of desalinated water with nonionization, 48 ml of 1N. sulfuric acid solution and 3 g of 10% palladium on coal, used as a catalyst, and hydrogenation is carried out. The hydrogenation process is monitored by thin layer chromatography using solvents as an eluent, consisting of ethyl acetate, pyrccin, acetic acid, and water in a ratio of
0
five
0
five
0
five
30: 20: 6: 11 (R - value of the starting compound 0.9, intermediate product 0.7 and final product 0.4) After the completion of the reaction, the catalyst is filtered and washed three times with desalted water with ionization with 30 ml each time last. The combined filtrate and the liquid obtained during the washing are evaporated on a rotary evaporator to a volume of 100 ml. The aqueous residue is diluted with demineralized ionization with water to approximately 200 ml. If the pH value does not fall between 6 jO and 6.5, it is brought to this limit by adding O, n. sulfuric acid solution, jiOTbi, ion exchanger in OH-form (for example, AG 1X8). Immediately thereafter, lyophilization is carried out.
yield 12.4 g (75%). 0.39- 0.47. -13G (with 1, water).
Calculated,%: C 46,07 | H 7.13; N 15.35; S 5.12.
C ,, H520zNb 7/8 () - 2.5 () (547.37)
Found,%; C46.4; H7.2; N 15.05; S 5,0. ,
The starting materials are prepared as follows.
L-Benzyloxycarbonyl-K-methyl-B-phenylalanine-L-proline.
Stage A. Benzyloxycarbonyl-B-phenyl-alanine 2,4,5-Trichlorophenyl ether.
60.0 g (0.2 mol) of benzyloxycarbonyl-B-phenylalanine and 39.4 g (0.2 mol) of 2,4,5-trichlorophenol are dissolved in 200 ml of tetrahydrofuran, the solution is cooled to 5-10 ° C, after which the cooled solution is stirred for approximately 30 minutes with stirring with 41.2 g (0.2 mol) of dicyclohexylcarbodiimide, then the reaction mixture is stirred for 6 hours without cooling. The dicyclohexylcarbamide precipitated out is filtered off, washed three times with tetrahydrofuran, each time using 50 ml of the latter, and the combined tetrahydrofuran solutions are evaporated in vacuo. The residue obtained is recrystallized from hot ethyl alcohol. The crystalline product is filtered off, washed twice at 5-10 ° C with ethyl alcohol, each used
0
five
0
five
0
five
0
five
0
139D1 methyl 3, 79;
once in 50 ml of the latter, and dried in a vacuum desiccator.
Output 72 g (75%), so pl. 141 ° C. + 37 ° (with 1 formamide),
Calculated,%: C 57.70; H N 2.92; C1 22.22.
(478.75) Found,%: C 57.7; H 3.9; N 3,0; C1 22.2.
Stage B. Benzyloxycarbonyl-D-phenylalanine-L-proline.
71.8 g (0.15 mol) of benzyloxycarbonyl-C-phenylalanine 2,4,5-trichlorophenyl ether (Example 1, Step A) is dissolved under stirring at room temperature in 180 ml of anhydrous pyridine, and then the prepared the solution is mixed with 17.3 g (0.15 mol) of L-proline and 21.0 ml (0.15 mol) of triethylamine. Stirring is continued until complete solution, no L-proline. The reaction mixture is then held for 4-6 hours, immediately after that it is evaporated to a volume of 80-100 ml in a water bath at a temperature of maximum 40 ° C and a pressure of 13-20 mbar, after which the residue is mixed with 250 ml water and 90 ml of diethyl ether. The aqueous phase is extracted twice with diethyl ether, each time using 30 ml of the latter, the combined ethereal solutions are washed twice with 5% sodium hydrogen carbonate solution, in particular; each time with 30 ml of this solution, and then the combined aqueous. the solutions are acidified to pH 2 by adding 3 n. hydrochloric acid solution. The oily substance that was precipitated was extracted three times with ethyl acetate and each time 120 ml of the latter, the combined product solutions in ethyl acetate were washed three times with water, each time 40 ml of the latter, dried over anhydrous sodium sulfate, and then evaporated in a water bath to 50-100 ml at a temperature of maximum 40 ° C and a pressure of 15-20 mbar. The residue obtained is recrystallized from 200 ml of diethyl ether.
The crystalline product is filtered; there are two times washed with diethyl ether, each time using
7
AO ml of the latter, and dry heh.
Yield 50.4.g (85%). T. 133 ° C. -46,4 (with tilformamide). R p 0.5.
Calculated,%: C 66.65; N 7.07

(396.43)
Found,%: C 66.4; H 6.25, N 7.2.
Step C. Cyclohexyl ammonium salt of K-benzyloxycarbonyl-N-methyl-B-phenylalanine-L-proline.
39.6 g (0.1 mol) of benzyloxycarbonyl-B-phenylalanine-b-proline (Example 1, Step B) and 50 ml (0.8 mol) of methyl iodide are dissolved in 300 ml of anhydrous tetrahydrofuran. The prepared solution is cooled to 0 ° C, after which, with stirring, 13.2 g (0.3 mol) of sodium hydride is added in portions to it, the number of portions being 8-10, then stirring is continued at room temperature within 2 hours. Immediately thereafter, 500 ml of ethyl acetate are added to the reaction mixture to decompose the sodium hydroxide formed, and a further 10 ml of water are added carefully to decompose excess sodium hydride. Then the solution is evaporated in a water bath at a temperature of at most 40 ° C and a pressure of 15-20 mbar. The residue is dissolved in 250 ml of water and 100 ml of diethyl ether, the aqueous phase is washed with 100 ml of diethyl ether, after which the combined ether solutions are washed with 50 ml of 5% sodium hydrogen carbonate. The sodium carbonate solution and the aqueous phase are combined, acidified by the addition of 5N. a solution of potassium sulfate to pH 2, and then twice extracted with ethyl acetate, using each time 150 ml of the latter. The combined product solutions in ethyl acetate are consequently washed with 100 ml of water, 50 ml of 10% sodium thiosulfate solution, again with 100 ml of water, dried the organic phase over anhydrous sodium sulfate, and then evaporated in a water bath at a temperature maximum and pressure of 15-20 mbar. The resulting residue
five
0
five
dissolved in 600 ml of benzene, the solution is mixed with 12 ml (0.105 mol) of cyclohexylamine, after which the mixture is kept overnight at room temperature. The crystalline product which has precipitated out is filtered, washed twice with benzene, using 200 times each time. ml of the latter, and then dried in a vacuum desiccator over paraffin chips.
The yield of 38.2 g (75%). R 0.53-0.60 (cyclohexylamine 0.01-0.05). T. pl. 160-163 ° C. Г «(7д + 12,1 ° (с 1., methyl alcohol).
Calculated,%: C 68.34; H 7.71; N 8.25.
C23H2f05-N2-Cj, H, 3N (509.63).
Found,%: C 68.5; H 7.8; N 8.3 ..
N-tert-butyloxycarbonyl-N-benzyloxycarbonyl-b-arginine-lactam.
Stage D. N-tert-Butyloxysicarbonyl-K-Benzyloxycarbonyl-b- arginine hydrate,
65.8 g (0.2 mol) of tert-butyloxy-arbonyl-b-arginine hydrate chlorine hydrate is dissolved in 100 ml 4 n. solution of sodium hydroxide, the prepared solution is cooled to 5, then with stirring it is mixed with 80 ml (0.5 mol) of benzyloxycarbonyl chloride and with ml of 4 n sodium hydroxide solution so that the pH value of the solution is above 12. Immediately after that The reaction mixture is additionally stirred for 3-4 hours, then diluted with the addition of 150 ml of water, after which the mixture is extracted with 100 ml of diethyl ether. Three phases were formed. The two lower phases are washed twice more with diethyl ether, each time using 100 ml of the latter, mixed with 300-400 ml of methyl alcohol in order to homogenize the phases, after which the pH value of the solution, if necessary, is adjusted to 12 (add 0 4N sodium hydroxide solution). The solution is incubated for 6-8 hours, and then it is extracted twice with a mixture of diethyl ether of acetic acid and petroleum ether-5, taken in a 1: 1 ratio, the pH value is adjusted to 6-7 by adding acetic acid ( -; clearly 50 ml), produced three times
0
five
0
five
extraction with methylene chloride, each time using 140 ml of the latter. Solutions of the product in methylene chloride are combined, washed twice with water, each time using 60 ml of the latter, and then evaporated in a water bath at a pressure of 25-30 mbar. The resulting residue is mixed with 300 ml of benzene and .600 ml of the mixture for 2–3 hours at 2020 ° C, then left overnight at. The precipitated crystalline product is filtered off, washed successively with 300 ml of water and 300 ml of benzene, and then dried in a vacuum desiccator over phosphorus pentoxide and darafin chips.
Yield 60 g (70%). T. pl. 122-124 C. -20 7 ° (c 1, pyridine). .
water, sew when
C 53.51; H 7.09;
gH280 N4-H20 (426.46)
C 53.35; H 7.2;
Calculated 13.14. WITH
Iv.
Found% 13.1.
Stage E. N Tert -Butyloxycarbonyl-lSn-benzyloxycarbonyl-L-paraginlactam.
59.7 g, (mol) of N-tert-butyloxycarbonyl-S-benzoyl sycarbonyl-b-arginine hydrate: (Example 1, stage D) and 19.6 g (0.14 mol) of triethylamine are dissolved in 200 ml of tetrahydrofuran a. The prepared solution is cooled to -10 ° C, after which, at this temperature and with stirring, it is first mixed with 18.5 ml (0.14 mol) of isobutyloxycarbonyl chloride, and then after 10 min with 19.6 ml (0.14 mol a) triethylamine. The reaction mixture was stirred for 1 hour at 0 ° C and for another 1 hour without cooling. After the completion of stirring, the mixture was poured into 1 liter of ice water. The precipitated crystalline product is filtered off, washed twice with ice water, every time 100 ml of the latter is used, and immediately thereafter dissolved in 280 ml chloroform. The chloroform plant is washed with 100 ml of ice water, dried over anhydrous calcium and a temperature of maximum 40 ° C and a temperature of 20-25 mbar are evaporated in a water bath. Crystal
38420310
The plastic residue is suspended in 70 ml of petroleum ether, the product is filtered off, washed twice with petroleum ether, each time 30 ml of the latter are used, and dried in a vacuum desiccator over phosphorus pentoxide.
Yield 44 g (81%). T pl. 164-166 ° C. -24 ° (s 1, tetrahydrofuran).
%: C 58.44; H.6.71;
ten
15
20
25
thirty
40
35
45
50
55
N
N
. (390.43)
C 58.7; H 6.8;
Calculated .14,45.
With „Нг, 0, GM.
Found -%; 14.1.
Example 2. N-ethyl-B-phenylalanine-b-prolyl-b-arginine aldehyde sulphate.
Stage 1. N-Benzyloxycarbonyl-. -K-ethyl-b-phenylalanine-b-prolyl-H - -benzyloxycarbonyl-b-arginine-lactam. . .
2.1 g (0.005 mol) of N-benzyloxycarbonyl-N-ethyl-B-phenylalanine-L-proline and 2.15 g (0.0055 mol) of N-tert.-butyloxycarbonyl-N -benzyloxycarbonyl Bonil-b-arginine-lactam (Example 1, Step E) is introduced into the reaction or condensation reaction (according to the method described in Example I, Step 1), using proportional amounts of the reagent and solvents; When processing the reaction mixture and during the chromatography on a column, the fractions are examined using thin-layer chromatography using a mixture of benzene and toluene (8: 2) as an eluent. The fractions which contain the pure main product (Rp 0.4-0.5) are combined, evaporated in a water bath. at a temperature of 40 ° C and a pressure of 15-20 mbar, the residue is treated with diisopropyl ether, filtered, washed with diisopropyl ether and dried in a vacuum desiccator over sulfuric acid and paraffin chips.
Yield 1.9 g (54%). Rj. 0.75-0.85.
Stage 2. N-Benzyloxycarbonyl-K-ethyl-B-phenylalanine-L-prolyl-K - -benzyloxycarbonyl-L-arginineldehyde. .
1.4 g (0.02 mol) of N-benzyloxycarbonyl-K-ethyl-B-phenylalanine-L-proyl-c-bbenzyloxycarbonyl-b-arginine-lactam (Example 2, step 1) is introduced into the interaction is analogous to
py 1, stage 2, when using proportional amounts of reagents.
The output of 1.15 g (72%) of the product, which in accordance with the data of elemental analysis contains 1 mol
cyclohexane.
contains RF
0.55-0.65. C, 67.49; H 7.47;
3.5 (N)
ten
25
thirty
Calculated N 10.73.
CjeH4607N6 CgH, 2 (782.95)
Found,%: C 67.6; H 7.5; N 10.5.
Step 3. K-ethyl-B-phenyl-alanine-b-prolyl-b-arginine aldehyde sulfate.
0.78 g (0.001 mol) of N-benzyloxy-15 carbonyl-K-ethyl-B-phenylalanine-b-prolyl-N-benzyloxycarbonyl-b-arginine aldehyde (Example 2, step 2) is reacted in a similar way to Example 1, stage 3, when using 20 proportional amounts of reagents and solvents.
Yield 0.75 g (70%). Rp 0.4-0.5.
Calculated,%: C 45.93; H 7.48; N 14.61; S 4.64. С25Нз40зНй- 5/6 () (573.27).
Found,%: C46.1; H7.6; N 14.2; S 4,6.
The starting compound, namely N-benzyl-oxycarbonyl-N-ethyl-D-phenyl-alanine-b-proline, can be prepared as follows. .
Stage A. K-ethyl-B-phenylalanine.
8.25 g (0.05 mol) of D-phenylalanine is dissolved in 100 ml of 20% aqueous ethyl alcohol. The prepared solution is mixed with 5.65 ml (0.1 mol) of acetic aldehyde and 2 g of 10% palladium on coal, used as a catalyst, and then for 2 days. Proi: Starts Hydrogenation. Then the catalyst is filtered off, washed with 60 ml of 2 N, hydrochloric acid solution, after which the pH of the aqueous solution is adjusted to a value of 7 by adding 4 k. Of sodium hydroxide solution, the product is filtered into a precipitate, washed three times, with water, apply each time 20 ml of the latter, and dried in a vacuum desiccator over anhydrous calcium chloride.
The yield of 4.85 g (50%). -53 ° (with 1, .0.1 N. sodium hydroxide solution),
Calculated,%: C 68.37; H 7.82; N 7.25.
35
40
45
50
55
0
five
0
50
five
0
five
0
five
C ,, H ,, 0, N (193.24)
Found,%: C 68.5; H 7.65; N 7.2.
Step B. N-Benzyloxycarbonyl-N-ethyl-D-phenylalanine.
2.9 g (0.015 mol) of L-ethyl-B-phenylalanine (Example 2, step A) are dissolved in 22.5 ml of a 2N sodium hydroxide solution. The prepared solution is mixed first with 10 ml of dioxane, and then after cooling to 5-10 ° C with 2.5 ml (approximately 0.017) of benzyloxycarbonyl chloride, after which the reaction mixture is stirred while cooling for 3 hours. After that, the reaction mixture diluted by adding 40 ml of water and then extracting 30 ml of a mixture consisting of diethyl ether and petroleum ether in a 1: 1 ratio. The result is a three-phase system. The two lower phases are again extracted with 300 ml of diethyl ether, and the combined aqueous phases are acidified with 1N. solution of sulfuric acid (pH 2). The precipitated product was extracted three times with ethyl acetate, using 30 ml of the latter each time. Solutions of the product in ethyl acetate-acetic acid are combined, washed twice with water, each time taken in an amount of 20 ML-, dried over anhydrous sodium sulfate, and then evaporated in a water bath at a temperature of 40 ° C. and a pressure of 15-20 mbar.
The yield of 2.7 g (55%) of oily product. RP 0.5-0.6.
Stage C. N-benzyloxycarbonyl- -N-ethyl-B-phenylalanine-L-proline.
2.6 g (0.008 mol) of N-benzyloxy-carbonyl-K-ethyl-B-phenyl-lanine (example 2, step 2) is dissolved in 10 ml of tetrahydrofuran. The prepared solution at 0 ° C is mixed with 1.6 g (0.008 mol) of 2,4,5-trichlorophenol and 1.65 g (0.008 mol) of dicyclohexyl-carbodiimide, after which the reaction mixture is kept for 4 hours at room temperature. The reaction mixture is then filtered and the filtrate is evaporated in a water bath at a temperature of maximum 40 ° C and a pressure of 15-20 mbar. The residue obtained is dissolved in 40 ml of benzene, the solution is washed twice with a 5% solution.
15
20
acidic sodium carbonate, each time using 20 ml of this solution, twice with water, which each time take in the amount of 20 ml. Immediately after this, the solution is dried over sodium sulfate and then evaporated in a water bath at a temperature of maximum 40 ° C and a pressure of 15-20 mbar. The oily plant residue — Q is thrown into 10 MP of pyridine, the solution is first mixed with 0.92 g (0.008 mol), L-proline, then C; 1.12 MP (0.008 mol) of triethylamine, after which the reaction mixture is stirred at room temperature until the L-proline is completely dissolved. The solution is kept for JB for 4–5 h and immediately thereafter evaporated, in a water bath at a maximum temperature and pressure of 15– ;; 20 mbar. The residue obtained is dissolved in 25 ml of water and 10 ml of distillate ether, the aqueous phase is washed twice with diethyl ether 5 using 25 each time .10 ml of the latter, and the combined ether solutions are washed twice with a 5% solution of acid carbonate. sodium, each time using 10 ml of this solution. The combined aqueous phases are acidified to pH 2 by adding 3 n. hydrochloric acid solution. The precipitated product is extracted three times with benzene, each time using 15 ml of the latter, the combined benzene extracts are washed three times with water, which is always taken in an amount of 5 ml, dried over anhydrous sodium sulphate and then evaporated on a water bath at and a pressure of 15-20 mbar.
Yield 2.2 g (64%) of oily product. RP 0.5-0.6.
EXAMPLE 3 N-isobutyl-B-phenylalanine-b-prolyl-b-arginine aldehyde sulphate.
Stage 1, N-Benzyloxycarbonyl-N-isobutyl-B-phenylapanine-b-prolyl-N-benzyloxycarbonyl-b-arginine-. lactam. 2, 26 g (0.005 mol) N-benzyl-; Sicarbonyl-K-isobutyl-p-phenylalanine-L-proline and N-tert-butyl-oxycarbonyl-N -benzyloxycarbonyl-L-ap-ginin-lactam (Example 1, step E) 55 are brought into interaction or in the condensation reaction as in example 1, when using proportional ko30
35
40
45
50
0
five
five
0
five
0
five
0
reagents and solvents. . When processing the reaction mixture and in the course of chromatography on a column, the fractions are examined using thin layer chromatography in a solvent mixture consisting of ethyl ester of acetic acid, pyridine, acetic acid and water 480: 20: 6: 11, and fractions which contain the pure product with R p 0.75-0.85, are combined. Then these fractions are evaporated in a water bath at 40 ° C and at a pressure of 15–20 mbar, the resulting residue. treated with petroleum ether, filtered, the product is washed with petroleum ether and dried in a vacuum desiccator with paraffin chips .-.
Yield 2.7 g (75%). RP 0.75-0.85, J 5.8 (s, tetrahydrofuran).
Calculated,%: C, 66.30; H 6.95; N 10.87.
C4oH4gO, N, -2/3 (C4HgO) (772.90)
Found,%: C 65.0; H 6.8; N 10.80.
Step 2. N-benzyloxycarbonyl-N-isob util-D-phenylalanine-L-prolyl-N-benzyloxycarbonyl-L-arginine aldehyde,
1.45 g (0.002 mol) of N-benzyloxy-, carbonyl-L-isobutyl-B-phenylalanine -L-nponkn-N -benzyloxycarbonyl-b arginine lactam; (Example 3, stage 1); restore as in Example 1, stage 2, using proportional amounts of reagents and solvents.
Yield 1.0 g (62%). RP 0.24. C.) + 2.3 ° (s. G, tetrahydrofuran).
Calculated,%: C, 66.64; H 7.14; N11.24.
C4flHj 0, () (747.89).
Found,%: C 66.3; H 7.1; N 11.2.
Stage 3. N-isobutyl-D-phenylalanine b-prolyl-b argininal- sulphate; - degida.
0.81 g (0.001 mol) of N-benzyloxy carbonyl-S isobutyl-B phenylalanine-β-prolyl-to-benzyloxycarbonyl-b-arginine aldehyde (Example 3, Step 2) is reacted in a manner similar to Example 1, Step 3 , when using proportional amounts of reagents and solvents.
Yield 0.45 g (80%), RF 1 0.64.
Calculated,%: C 45, .84; H 7.69; N 13.36; S 5.1.
Cz, NsO, S, HjS04 4 CH, 0) (628.74)
Found,%: C 45.8; H 7.2; N 13.4; S 4.9.
The starting compound, namely K-benzyloxycarbonyl-K-isobutyl-B-phenylalanine L-proline, can be prepared as follows.
Stage A. N-Isobutyl-D-Phenyl Nin.
As a starting material, 8.25 g (0.05 mol) of D-phenylalanine was used and the method was carried out as in Example 2, step A, with the difference that instead of acetaldehyde, 9.1 ml (0.1 ml) were used. mole of isomaldehyde.
Yield 8.7 g (70%), -29.9 ° (c 1, 0.1 N. sodium hydroxide solution).
Calculated N 6,08.
%: C, 67.79; H 8.75;
;, jH ;,
N
1/2 () (230.30)%: C 67.2; H 8.9;
Found 6.15.
Stage B, N-Benzyloxycarbonyl-. -N-i.zobyl-D-phenylalanine.
3.32 g (0.015 mol) of N-isobutyl-P-phenylalanine (Example 3, Step A) are reacted as in Example 2, Step B.
Yield 3.2 g (60%) of oily product. RP 0.6-0.7. .
Stage C. N-Benzyloxycarbonyl- -Y-isobutyl-B-phenylalanine-L proline.
2.85 g (0.008 mol) of N-benzyloxy-carboxylic N-isobuty-D-phenylalanine (example 3, stage B) are reacted as in example 2, stage C-.
Yield 2.45 g (67%) of an oily product, RP 0.65-0.70.
Biological tests of the peptidyl-arginine aldehyde derivatives obtained under the conditions of the proposed method are carried out.
When conducting special studies, peptides are dissolved in water (pH 6.0) at concentrations of 10 mg / cm, after which the solutions are stored at 40 ° C for 5 days. observe the change in antithrombin activity of the solute. The characteristic activity value is determined in a system that consists of
the following components, see
3
0
five
0
five
0
five
0
five
0
five
0.5% bovine fibrinogen in 0.9% sodium chloride solution 0.2; a buffer solution containing tris- (oxymethyl) -aminomethan and hydrogen chloride (pH value 7.2), which also contains a solution of the peptide under study, 0.3; 5 units / cm of US Standard Human Thrombin solution (NIH, Bethesda, Maryland, CIUA), 0.1.
The clotting time of this system without the addition of peptide was 15 seconds in a Schnither Gross Coagulomefer instrument.
The initial retarding blood clotting activity of the individual tripeptide-aldehyde sulphates is indicated by such a molar concentration, which, in comparison with the control experiment, causes a fivefold lengthening. clotting time (1 d-value).
The measured on the first, third and fifth days of the antithrombin activity of individual peptides in aqueous solution at pH 6.0 and -40 ° C from the initial activity (zero days) are given in Table. one.
During the observation period, the initial activity of D-phenyl-alanine-L-prolyl-b-arginine aldehyde sulfate is halved, while the N-methyl derivative retains its original activity, and the activity of N-ethyl and N-isobutyl connections are reduced only
by 15-20%. In terms of conditions 1
The experiments should be considered as partial re-realization of the L-arginine aldehyde at the end of the molecule. This may explain a slight drop in the activity of the N-ethyl or N-isobutyl derivative.
The effect of N-alkyl tripeptide pyridine on the plasminfibrin reaction is also examined and determined by the example of N-methyl-B-phenylalanine-L-prolyl-L-argininealdehyde sulfate in the following system, 0.05% bovine fibrinogen in 0 , sodium chloride solution, 0.2; containing tris- (hydroxymethyl) -aminomethane and hydrogen chloride buffer solution (pH value 7.2), which also contains the peptide under study 0.1; US Standard Human Thrombin (NIH) Bethesda solution, Maryland, USA / 10 units / cm 0.1; 0.1 units
plasmin in 0.1 ml of the buffer solution (KABI, Stockholm, Sweden).
The coagulation time of the fibrin gel that formed in the system without the addition of peptide is 10 minutes,
D-phenylalanine-L-prolyl-b-arginine aldehyde sulfate and tert-butyloxy-hemisulfate are used as the control compound. carbonyl-B-phenylalanine-b-prolyl-b- -arginine pegde.
The effect of tripeptide aldehydes on the plasminfibrin reaction is shown in Table. 2 (dissolution time of fibrinous clots without peptide added 10 minutes). ..
From the table. 2 data shows that N-alkylated tripeptide aldehyde behaves as known, containing a free amino group at the end. With small quantities, the formed clots dissolve within a control period, with large quantities, clots either do not form at all or are formed with a weak gel structure. At the same time, depending on the concentration, the hemisulfate of acyl tripeptidyldehyde lengthens the hydrolysis time of plasmin of fibrinous clots.
From the studies described, it follows that new tripeptidaldehydes with upylated terminal amygroups have much greater stability than the known sulfate C-phenethalanine-L-prolyl-B-argininealdehyde, but at the same time they are similar selective coagulants of coagulation, because do not affect the plasmin fibrin response.
The new N-alkyl tripeptide aldehydes of the proposed formula possess in vivo a significant inhibitory blood clotting activity. In the studies, the peptides were administered orally through the mouth or intravenously to New Zealand hares (weight 2-3 kg), and the peptides were administered in saline. For intravenous administration, for 3 hours, infusions with doses of 0.5-2.0 mg / kg / hr are administered at a rate of 6 ml / 20-30 mg / kg of peptide dissolved in a volume of 2 ml is ingested through the mouth. . After administration at intervals of 30 minutes from the caudal vein, the selection
blood samples are taken, after which the clotting time of the whole blood is determined in the thrombo-elastograph, and the plasma-thrombin reaction time is also measured simultaneously.
Braking coagulation in vivo action. The N-alkyl tripeptide aldehydes in experiments on male New Zealand hare are shown in Table. 3. The cited table. 3, the data show that N-alkyl tripeptide aldehydes have equal or similar activity compared to the substance used for comparison.
Based on intravenous injection studies carried out on rabbits, the dose for humans with intravenous administration of 1-2 mg / kg / h has been established.
The tests carried out show that N-alkyl (C, -04) -derivatives of peptidyl aldehyde sulfates slightly lose their initial activity (N-methyl and N-isobutyric derivatives lose activity by 15–20% ), while the reference compound is deactivated by 60% over this period.
. In addition, new tripeptide aldehydes with alkylated terminal amino groups are more stable than the well-known B-phenylalanine-L-prolyl-L-arginine aldehyde sulfate, but at the same time they are similar selective inhibitors of coagulation, since with effective inhibition of thrombin-fibrinogen reaction they do not affect the plasmin fibrin response.

权利要求:
Claims (1)
[1]
Invention Formula
The method of producing peptidyl-arginine aldehyde sulfates of the general formula
five
0
R
one
AT
DPhe-ppo-A-H-HoSO,
2
Where
R. R is hydrogen;
C, -C4 alkyl, moreover, R., and R
attached to the amino group
D-phenylalanine; A - L-arginine residue, characterized in that arginine-lactam with protected guanidine group is condensed with a K-monoalkyl () - L-proline protected by a terminal amino group of the dipeptide; the obtained tripeptide lactam is reduced to the corresponding tripeptide aldehyde and after cleavage of the protecting group, the desired products are isolated as a salt.
N-methyl-D-phenylalanine-b-pro-lil-b-arginine aldehyde sulfate
N-ethyl-B-phenylalanine-L-prolyl sulfate-L-arginine aldehyde 0.21
N-isobutyl-B-phenylalanine-L- -prolyl-b arginine aldehyde sulfate
D-phenylalanine-b-prolyl-b-arginine aldehyde sulfate (substance for comparison) 0.35
The concentration of the peptide in the reaction mixture ((UM) j, which, in comparison with the control experiment, causes a five-fold lengthening of the clotting time.
Spreadsheets
0.25,100
100
100
100
100
100
100
85
0.31
100 100
85
80
100
100
50
40
table 2
2, l-)
: I
D-Phenylalanine Sulphate
-L-prolyl-b-argininealdehyde
Tert-Butyl oxycarbonyl-B-phenylalanine-b-prolyl-b-arginine hemisulphate
aldehyde
Dissolution time cannot weak structure
g
T
Tripeptide aldehyde
N-methyl-D-phenylalanine-b-prolyl-b-arginine aldehyde sulfate
K-ethyl sulfate
-D-phenylalanine-b-shed-b-argy
Ninaldehyde
N-isobutyl-B-phenylalanine-b-prolyl-b-arginine aldehyde sulfate
D-phenylalanine-b-prolyl-b-argynonaldehyde sulfate (substance for comparison)

类似技术:

公开号 | 公开日 | 专利标题

SU1384203A3|1988-03-23|Method of producing peptidyl-arginine-aldehyde sulfates

US4478745A|1984-10-23|T-Butyloxy-carbonyl-D-phenylalanyl-L-prolyl-L-arginine aldehyde hemisulfate, D-phenylalanyl-L-prolyl-L-arginine aldehyde sulfate and process for the preparation thereof

EP0509080B1|2000-08-16|Inhibitors and substrates of thrombin

RU2024549C1|1994-12-15|Glycine derivatives or their physiologically acceptable salts showing capability to inhibit fibrinogen binding in fibrinogen platelet receptor

US5627283A|1997-05-06|Amidinophenylalanine derivatives, a process for the preparation thereof, use thereof and agents containing these as anticoagulants

AU663169B2|1995-09-28|New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof

US4713369A|1987-12-15|Oligopeptidylargininol derivatives and their homologs, a process for their preparation, their use and agents containing them

SK63194A3|1994-12-07|Peptide derivatives

RU1836382C|1993-08-23|Method for obtaining derivatives of dipeptides or their pharmaceutically acceptable salts

EP0244083A2|1987-11-04|Amino acid derivatives

EP0009010A1|1980-03-19|Bradykinin inhibiting tripeptide derivatives, process for their preparation and pharmaceutical preparations containing them

US5274098A|1993-12-28|Amidinophenylalanine derivatives, process for their preparation, their use and compositions containing them

DK172011B1|1997-09-15|Amino Alcohol Peptide Derivatives, Process for Preparation thereof and Pharmaceutical Preparations Containing the Derivatives

JP2000512278A|2000-09-19|Anti-coagulable peptidyl-arginine aldehyde derivative

US3793304A|1974-02-19|Cyclic decapeptides comprising an l-tyrosine radical

SU1028663A1|1983-07-15|Analogs of leuliberine having inhibiting effect on process of ovulation in animals

US6387881B1|2002-05-14|Inhibitors and substrates of thrombin

KR0147817B1|1998-08-01|Method for producing tripeptide aldehydes

SU1148560A3|1985-03-30|Method of obtaining substituted acul derivative of 1,2,3,4-tetrahydroisoquinoline--3-carboxylic acid or pharmaceutically accepted salts

GB2244994A|1991-12-18|Preparation of tripeptide aldehydes

IE61522B1|1994-11-16|Improved process for the prepartion of tripeptide aldehydes

KR20040062942A|2004-07-09|Peptide arginals and methods for treating disseminated intravascular coagulation

HU211088B|1995-10-30|Process for producing peptide derivates inhibiting coagulation of blood and pharmaceutical compositions containing them

DK144562B|1982-03-29|PROCEDURE FOR PREPARING CYSTE CONTAINING PEPTIDES

同族专利:

公开号 | 公开日

FI85980C|1992-06-25|

EP0185390A3|1988-09-07|

FI855118A|1986-06-22|

HUT38954A|1986-07-28|

PT81746B|1987-11-11|

ES550296A0|1987-10-01|

ZA859756B|1986-09-24|

AT68002T|1991-10-15|

HU192646B|1987-06-29|

DK596385D0|1985-12-20|

GR853121B|1986-04-22|

AU585561B2|1989-06-22|

EP0185390A2|1986-06-25|

ES8708237A1|1987-10-01|

EP0185390B1|1991-10-02|

PT81746A|1986-01-01|

CA1261547A|1989-09-26|

US4703036A|1987-10-27|

JPH0680078B2|1994-10-12|

AR241710A1|1992-11-30|

DK171403B1|1996-10-14|

IL77416A|1990-04-29|

CN1025738C|1994-08-24|

FI855118A0|1985-12-20|

FI85980B|1992-03-13|

DK596385A|1986-06-22|

JPS61152699A|1986-07-11|

AU5155385A|1986-06-26|

CN85109736A|1987-03-18|

DE3584281D1|1991-11-07|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

HU177098B|1979-01-04|1981-07-28|Gyogyszerkutato Intezet|Process for producing new peptidyl-n-carboxy-l-arginin-a|

CA1161431A|1979-05-11|1984-01-31|Lars G. Svendsen|Tripeptide derivatives|

HU184368B|1981-01-13|1984-08-28|Gyogyszerkutato Intezet|Process for preparing d-phenyl-alanyl-l-propyl-l-arginine-ald ehyde-shulphate|

US4434096A|1981-06-30|1984-02-28|E. I. Du Pont De Nemours And Company|Substrates for the quantitative determination of proteolytic enzymes|

US4448717A|1982-11-12|1984-05-15|Eli Lilly And Company|Pharmacologically active peptides|

DE3244030A1|1982-11-27|1984-05-30|Behringwerke Ag, 3550 Marburg|CHROMOGENIC COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR USE|

CA1267499A|1983-07-12|1990-04-03|Cedric H. Hassall|Peptide amides and aldehydes|JPH075634B2|1987-10-30|1995-01-25|日東紡績株式会社|Tripeptides and antiplasmin agents containing the same|

GB2244994B|1990-06-12|1994-01-19|Richter Gedeon Vegyeszet|Improved process for the preparation of tripeptide aldehydes|

IL99527A|1990-09-28|1997-08-14|Lilly Co Eli|Tripeptide antithrombotic agents|

US5430023A|1990-09-28|1995-07-04|Eli Lilly And Company|Tripeptide antithrombotic agents|

EP0503203A1|1991-03-15|1992-09-16|Merrell Dow Pharmaceuticals Inc.|Novel thrombin inhibitors|

US5391705A|1991-03-15|1995-02-21|Merrell Dow Pharmaceuticals Inc.|Polyfluorinated tripeptide thrombin inhibitors|

CA2071621C|1991-06-19|1996-08-06|Ahihiko Hosoda|Aldehyde derivatives|

CA2075154A1|1991-08-06|1993-02-07|Neelakantan Balasubramanian|Peptide aldehydes as antithrombotic agents|

ZA928581B|1991-11-12|1994-05-06|Lilly Co Eli|Antithrombotic agents|

US5416093A|1991-11-12|1995-05-16|Eli Lilly And Company|Antithrombotic agents|

US5252566A|1991-11-12|1993-10-12|Eli Lilly And Company|Antithrombotic agents|

IL108031D0|1992-12-22|1994-04-12|Procter & Gamble|Difluoro pentapeptide derivatives and pharmaceutical compositions containing them|

US5455229A|1992-12-23|1995-10-03|Eli Lilly And Company|Method for minimizing and containing ischemic and reperfusion injury|

US5672582A|1993-04-30|1997-09-30|Merck & Co., Inc.|Thrombin inhibitors|

WO1994025051A1|1993-04-30|1994-11-10|Merck & Co., Inc.|Thrombin inhibitors|

SE9301916D0|1993-06-03|1993-06-03|Ab Astra|NEW PEPTIDES DERIVATIVES|

US6984627B1|1993-06-03|2006-01-10|Astrazeneca Ab|Peptide derivatives|

US5783563A|1993-06-03|1998-07-21|Astra Aktiebolag|Method for treatment or prophylaxis of venous thrombosis|

US5436229A|1994-03-04|1995-07-25|Eli Lilly And Company|Bisulfite adducts of arginine aldehydes|

US5484772A|1994-03-04|1996-01-16|Eli Lilly And Company|Antithrombotic agents|

ZA951618B|1994-03-04|1996-08-27|Lilly Co Eli|Antithrombotic agents|

US5707966A|1994-03-04|1998-01-13|Eli Lilly And Company|Antithrombotic agents|

US5705487A|1994-03-04|1998-01-06|Eli Lilly And Company|Antithrombotic agents|

US5710130A|1995-02-27|1998-01-20|Eli Lilly And Company|Antithrombotic agents|

US5726159A|1994-03-04|1998-03-10|Eli Lilly And Company|Antithrombotic agents|

US5439888A|1994-03-04|1995-08-08|Eli Lilly And Company|Antithrombotic agents|

US5488037A|1994-03-04|1996-01-30|Eli Lilly And Company|Antithrombotic agents|

US5602101A|1994-03-04|1997-02-11|Eli Lilly And Company|Antithrombotic agents|

CA2143533A1|1994-03-04|1995-09-05|Kenneth D. Kurz|Antithrombotic agents|

US5914319A|1995-02-27|1999-06-22|Eli Lilly And Company|Antithrombotic agents|

US5885967A|1994-03-04|1999-03-23|Eli Lilly And Company|Antithrombotic agents|

DE4421052A1|1994-06-17|1995-12-21|Basf Ag|New thrombin inhibitors, their production and use|

NZ289562A|1994-06-17|1998-10-28|Corvas Int Inc|Solution phase and solid phase methods for the synthesis of peptidyl argininal derivatives and salts thereof|

US5514777A|1994-06-17|1996-05-07|Corvas International, Inc.|Methods of synthesis of peptidyl argininals|

SE9404196D0|1994-12-02|1994-12-02|Astra Ab|New antithrombotic formulation|

US6025472A|1994-12-21|2000-02-15|Corvas International, Inc.|N-substituted glycine derivatives as enzyme inhibitors|

US5696231A|1994-12-21|1997-12-09|Corvas International, Inc.|N-substituted glycine derivatives as enzyme inhibitors|

CN1198839C|1995-02-17|2005-04-27|艾伯特有限及两合公司|Novel dipeptide amidines as thrombin inhibitors|

SA96170106A|1995-07-06|2005-12-03|أسترا أكتيبولاج|New amino acid derivatives|

US6165966A|1996-09-24|2000-12-26|The Procter & Gamble Company|Liquid detergents containing proteolytic enzyme and protease inhibitors|

US6069232A|1995-10-02|2000-05-30|Hoechst Marion Roussel, Inc.|Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors|

TW541316B|1995-12-21|2003-07-11|Astrazeneca Ab|Prodrugs of thrombin inhibitors|

DE19549118C2|1995-12-29|2000-07-13|Thomas W Stief|Hemostasis activation inhibitor and method for inhibiting hemostasis activation in blood or other biological fluids|

DE19605039A1|1996-02-12|1997-08-14|Hoechst Ag|High yield and purity production of reversibly protected oligopeptide aldehyde|

US5739354A|1996-03-26|1998-04-14|Hoechst Marion Roussel, Inc.|Process for the preparation of N-methyl-D-phenylalanyl-N- 1- 3- amino!propyl!-3,3-difluoro-2-oxohexyl!-L-prolinamide|

HU224315B1|1996-06-05|2005-07-28|Gyógyszerkutató Intézet Kft.|Peptidyl-arginin-aldehyde derivatives of anticoagulant activity and pharmaceutical compositions containing them|

HU222199B1|1996-06-05|2003-05-28|Gyógyszerkutató Intézet Kft.|Peptid-aldehyde derivatives of anticoagulant activity and pharmaceutical compositions containing them|

SE9602263D0|1996-06-07|1996-06-07|Astra Ab|New amino acid derivatives|

SE9602646D0|1996-07-04|1996-07-04|Astra Ab|Pharmaceutically useful compounds|

CN1113088C|1996-09-24|2003-07-02|普罗格特-甘布尔公司|Liquid detergents containing proteolytic enzyme and protease inhibitors|

WO1998013461A1|1996-09-24|1998-04-02|The Procter & Gamble Company|Liquid laundry detergent compositions containing proteolytic enzyme and protease inhibitors|

US5798377A|1996-10-21|1998-08-25|Merck & Co., Inc.|Thrombin inhibitors|

AR013084A1|1997-06-19|2000-12-13|Astrazeneca Ab|USEFUL AMIDINE DERIVATIVES AS THROMBIN INHIBITORS, PHARMACEUTICAL COMPOSITION, USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES AND THE PROCESS FOR THE PREPARATION OF THE MENTIONED COMPOUNDS|

SE9704543D0|1997-12-05|1997-12-05|Astra Ab|New compounds|

AU751111B2|1998-01-26|2002-08-08|Basf Aktiengesellschaft|Thrombin inhibitors|

SE9804313D0|1998-12-14|1998-12-14|Astra Ab|New compounds|

EE200100371A|1999-01-13|2002-02-15|Astrazeneca Ab|Amidinobenzylamine derivatives and their use as thrombin inhibitors|

KR20020004971A|1999-03-16|2002-01-16|이경하|Substituted proline derivatives and medicinal compositions containing the same|

SE0001803D0|2000-05-16|2000-05-16|Astrazeneca Ab|New compounds i|

US6433186B1|2000-08-16|2002-08-13|Astrazeneca Ab|Amidino derivatives and their use as thormbin inhibitors|

AR035216A1|2000-12-01|2004-05-05|Astrazeneca Ab|MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS|

US7129233B2|2000-12-01|2006-10-31|Astrazeneca Ab|Mandelic acid derivatives and their use as thrombin inhibitors|

US6528503B2|2000-12-18|2003-03-04|Merck & Co., Inc.|Thrombin inhibitors|

AU3083602A|2000-12-18|2002-07-01|Merck & Co Inc|Benzylamine derivatives and their use as thrombin inhibitors|

US7144899B2|2001-02-09|2006-12-05|Merck & Co., Inc.|Thrombin inhibitors|

AR034517A1|2001-06-21|2004-02-25|Astrazeneca Ab|PHARMACEUTICAL FORMULATION|

KR20040062942A|2001-08-21|2004-07-09|아이박스 드럭 리서치 인스티튜트 리미티드|Peptide arginals and methods for treating disseminated intravascular coagulation|

US7084134B2|2002-05-02|2006-08-01|Merk & Co., Inc.|Thrombin inhibitors|

SE0201659D0|2002-05-31|2002-05-31|Astrazeneca Ab|Modified release pharmaceutical formulation|

US7781424B2|2003-05-27|2010-08-24|Astrazeneca Ab|Modified release pharmaceutical formulation|

SE0201661D0|2002-05-31|2002-05-31|Astrazeneca Ab|New salts|

US7795205B2|2004-04-12|2010-09-14|Canyon Pharmaceuticals, Inc.|Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor|

TW200827336A|2006-12-06|2008-07-01|Astrazeneca Ab|New crystalline forms|

US20110028397A1|2007-11-30|2011-02-03|Toezser Jozsef|Use of Urokinase Type Plasminogen Activator Inhibitors for the Treatment of Corneal Disorders|

CN103649292B|2011-07-01|2017-11-28|诺维信公司|Stabilized subtilisin composition|

WO2016001319A1|2014-07-03|2016-01-07|Novozymes A/S|Improved stabilization of non-protease enzyme|

CN107469379B|2016-06-07|2020-03-06|中国科学院大连化学物理研究所|Method for removing residual water-soluble organic solvent in sample|

BR112021023457A2|2019-07-01|2022-01-25|Basf Se|Compound, use of the compound, composition, and, methods for preparing the composition and a compound|

法律状态:
2005-05-10| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: MM4A Effective date: 20031221 |

优先权:

申请号 | 申请日 | 专利标题

HU844763A|HU192646B|1984-12-21|1984-12-21|Process for preparing new n-alkyl-peptide aldehydes|

[返回顶部]